Page last updated: 2024-08-23

sq-11725 and Cancer Syndromes, Hereditary

sq-11725 has been researched along with Cancer Syndromes, Hereditary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Drolet, B; Kanigsberg, N; Lara-Corrales, I; Liy-Wong, C; Ma, J; Pope, E; Sibbald, C	1

Trials

1 trial(s) available for sq-11725 and Cancer Syndromes, Hereditary

Article	Year
Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial. JAMA pediatrics, 2022, 01-01, Volume: 176, Issue:1 Topics: Administration, Oral; Adrenergic beta-Antagonists; Double-Blind Method; Equivalence Trials as Topic; Female; Hemangioma, Capillary; Humans; Infant; Male; Nadolol; Neoplastic Syndromes, Hereditary; Ontario; Propranolol; Prospective Studies; Treatment Outcome	2022

Article

Year

Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial.

JAMA pediatrics, 2022, 01-01, Volume: 176, Issue:1

Topics: Administration, Oral; Adrenergic beta-Antagonists; Double-Blind Method; Equivalence Trials as Topic; Female; Hemangioma, Capillary; Humans; Infant; Male; Nadolol; Neoplastic Syndromes, Hereditary; Ontario; Propranolol; Prospective Studies; Treatment Outcome

2022